The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer

Gynecologic Oncology

Volumn 123, Issue 2, 2011, Pages 411-420

  Naumann, R Wendel ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

AKT; Endometrial cancer; mTOR; PI3K; PTEN; Uterine cancer

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; AZD 2014; AZD 8055; BKM 120; BYL 719; EVEROLIMUS; GDC 0068; GDC 09041; GDC 0980; GESTAGEN; GSK 2141795; GSK 458; GSK 795; LETROZOLE; MEGESTROL ACETATE; MK 2206; MKC 1; OSI 027; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RIDAFOROLIMUS; TAMOXIFEN; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 147; XL 765;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; ANOREXIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CARBON MONOXIDE DIFFUSING CAPACITY; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL SURVIVAL; CHEMICAL PARAMETERS; DEREGULATION; DIARRHEA; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EPIGASTRIC PAIN; FATIGUE; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERLGYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MEDLINE; MONOTHERAPY; MOOD DISORDER; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMATITIS; SYSTEMATIC REVIEW; T WAVE INVERSION; THROMBOCYTOPENIA; UPREGULATION; UTERUS CANCER; VOMITING;

FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UTERINE NEOPLASMS;

EID: 80054718248     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.08.002     Document Type: Review

References (103)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. P.A. Wingo, T. Tong, and S. Bolden Cancer statistics, 1995 CA Cancer J Clin 45 1995 8 30
3. Centers for Disease Control and Prevention Differences in prevalence of obesity among black, white, and Hispanic adults - United States, 2006-2008 MMWR Morb Mortal Wkly Rep 58 2009 740 744
4. Centers for Disease Control and Prevention State-specific prevalence of obesity among adults - United States, 2007 MMWR Morb Mortal Wkly Rep 57 2008 765 768
5. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G.C. Reid, and A.R. Munkarah Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 22 2004 2159 2166
6. M.A. Sovak, J. Dupont, M.L. Hensley, N. Ishill, S. Gerst, and N. Abu-Rustum Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study Int J Gynecol Cancer 17 2007 197 203
7. American Cancer Society Estimated new cancer cases and deaths by sex, US 2009 [Internet]. ASC [cited Jan 2011]. Available from: http://www.cancer.org/ acs/groups/content/@nho/documents/document/500809webpdf.pdf
8. K.M. Moxley, and D.S. McMeekin Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents Oncologist 15 2010 1026 1033
9. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627 644
10. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
11. Y. Sugimoto, M. Whitman, L.C. Cantley, and R.L. Erikson Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol Proc Natl Acad Sci U S A 81 1984 2117 2121
12. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
13. B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, and J. Baselga Status of PI3K inhibition and biomarker development in cancer therapeutics Ann Oncol 21 2010 683 691
14. C. Gewinner, Z.C. Wang, A. Richardson, J. Teruya-Feldstein, D. Etemadmoghadam, and D. Bowtell Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling Cancer Cell 16 2009 115 125
15. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 2006 424 430
16. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
17. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 2006 606 619
18. R.J. Dowling, I. Topisirovic, B.D. Fonseca, and N. Sonenberg Dissecting the role of mTOR: lessons from mTOR inhibitors Biochim Biophys Acta 1804 2010 433 439
19. M.E. Pacold, S. Suire, O. Perisic, S. Lara-Gonzalez, C.T. Davis, and E.H. Walker Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma Cell 103 2000 931 943
20. P. Rodriguez-Viciana, P.H. Warne, A. Khwaja, B.M. Marte, D. Pappin, and P. Das Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras Cell 89 1997 457 467
21. S. Gupta, A.R. Ramjaun, P. Haiko, Y. Wang, P.H. Warne, and B. Nicke Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice Cell 129 2007 957 968
22. K.L. Guan, C. Figueroa, T.R. Brtva, T. Zhu, J. Taylor, and T.D. Barber Negative regulation of the serine/threonine kinase B-Raf by Akt J Biol Chem 275 2000 27354 27359
23. A.G. Renehan, J. Frystyk, and A. Flyvbjerg Obesity and cancer risk: the role of the insulin-IGF axis Trends Endocrinol Metab 17 2006 328 336
24. T. Pischon, U. Nothlings, and H. Boeing Obesity and cancer Proc Nutr Soc 67 2008 128 145
25. R.J. Pietras, and C.M. Szego Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells Nature 265 1977 69 72
26. T. Simoncini, E. Rabkin, and J.K. Liao Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells Arterioscler Thromb Vasc Biol 23 2003 198 203
27. E.R. Prossnitz, J.B. Arterburn, H.O. Smith, T.I. Oprea, L.A. Sklar, and H.J. Hathaway Estrogen signaling through the transmembrane G protein-coupled receptor GPR30 Annu Rev Physiol 70 2008 165 190
28. R.J. Dowling, M. Zakikhani, I.G. Fantus, M. Pollak, and N. Sonenberg Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 67 2007 10804 10812
29. M. Zakikhani, M.J. Blouin, E. Piura, and M.N. Pollak Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells Breast Cancer Res Treat 123 2010 271 279
30. J.L. Hecht, and G.L. Mutter Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 2006 4783 4791
31. F. Zagouri, G. Bozas, E. Kafantari, M. Tsiatas, N. Nikitas, and M.A. Dimopoulos Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int 2010 2010 749579
32. G.L. Mutter, M.C. Lin, J.T. Fitzgerald, J.B. Kum, J.P. Baak, and J.A. Lees Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers J Natl Cancer Inst 92 2000 924 930
33. L. Catasus, A. Gallardo, M. Cuatrecasas, and J. Prat Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis Mod Pathol 22 2009 522 529
34. K. Shoji, K. Oda, S. Nakagawa, S. Hosokawa, G. Nagae, and Y. Uehara The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas Br J Cancer 101 2009 145 148
35. X. Sun, J. Huang, T. Homma, D. Kita, H. Klocker, and G. Schafer Genetic alterations in the PI3K pathway in prostate cancer Anticancer Res 29 2009 1739 1743
36. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, and S.I. Wang PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
37. G.L. Mutter, T.A. Ince, J.P. Baak, G.A. Kust, X.P. Zhou, and C. Eng Molecular identification of latent precancers in histologically normal endometrium Cancer Res 61 2001 4311 4314
38. A.S. McCampbell, R.R. Broaddus, D.S. Loose, and P.J. Davies Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium Clin Cancer Res 12 2006 6373 6378
39. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, and S. Szabo High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
40. T. Okuda, A. Sekizawa, Y. Purwosunu, M. Nagatsuka, M. Morioka, and M. Hayashi Genetics of endometrial cancers Obstet Gynecol Int 2010 2010 984013
41. K. Uegaki, Y. Kanamori, J. Kigawa, W. Kawaguchi, R. Kaneko, and J. Naniwa PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma Oncol Rep 14 2005 389 392
42. H.B. Salvesen, S.L. Carter, M. Mannelqvist, A. Dutt, G. Getz, and I.M. Stefansson Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation Proc Natl Acad Sci U S A 106 2009 4834 4839
43. A.M. Oza, E.A. Eisenhauer, L. Elit, J.C. Cutz, A. Sakurada, and M.S. Tsao Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148 J Clin Oncol 26 2008 4319 4325
44. B. Slomovitz, K. Schmeler, D. Miller, K. Lu, P. Ramirez, and T. Caputo Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer Gynecol Oncol 116 2010 13 (abstract)
45. A.M. Oza, l Elit, J. Biagi, W. Chapman, M. Tsao, and D. Hedley Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160 J Clin Oncol 24 2006 3003 (abstract)
46. A.M. Oza, L. Elit, D. Provencher, J.J. Biagi, L. Panasci, and J. Sederias A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b J Clin Oncol 26 2008 5516 (abstract)
47. S.M. Temkin, S.D. Yamada, and G.F. Fleming A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies Gynecol Oncol 117 2010 473 476
48. G.F. Fleming, V. Filiaci, J. Hanjani, T.W. Burke, S. Davidson, and K. Leslie Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248 J Clin Oncol 29 2011 5014 (abstract)
49. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
50. B.M. Slomovitz, J.R. Brown, T. Johnston, D. Mura, C. Levenback, and J. Wolf A phase II study of everolimus and letrozole in patients with recurrent endometrial cancer J Clin Oncol 29 2011 5012 (abstract)
51. H. Mackay, S. Welch, M. Tsao, J. Biagi, L. Elit, and P. Ghatage Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192 J Clin Oncol 29 2011 5013 (abstract)
52. A. Oza, A. Poveda, A. Clamp, S. Pignata, G. Scambia, and J. Del Campo A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma J Clin Oncol 29 2011 5009 (abstract)
53. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, and D. Smith mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508
54. N. Carayol, E. Vakana, A. Sassano, S. Kaur, D.J. Goussetis, and H. Glaser Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells Proc Natl Acad Sci U S A 107 2010 12469 12474
55. S.V. Bhagwat, P.C. Gokhale, A.P. Crew, A. Cooke, Y. Yao, and C. Mantis Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin Mol Cancer Ther 10 2011 1394 1406
56. S. Jia, T.M. Roberts, and J.J. Zhao Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 21 2009 199 208
57. S. Kang, A. Denley, B. Vanhaesebroeck, and P.K. Vogt Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase Proc Natl Acad Sci U S A 103 2006 1289 1294
58. K. Shoji, K. Oda, S. Nakagawa, Y. Ikeda, H. Kuramoto, and M. Nishida Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines J Clin Oncol 28 2010 5074 (abstract)
59. K. Oda, K. Shoji, S. Nakagawa, T. Kashiyama, Y. Ikeda, and Y. Miyamoto Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas J Clin Oncol 29 2011 5110
60. J.B. Engel, A. Honig, T. Schonhals, C. Weidler, S. Hausler, and M. Krockenberger Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation Eur J Obstet Gynecol Reprod Biol 141 2008 64 69
61. M. Knowling, M. Blackstein, R. Tozer, V. Bramwell, J. Dancey, and N. Dore A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial Invest New Drugs 24 2006 435 439
62. C. Elser, H. Hirte, L. Kaizer, H. Mackay, S. Bindra, and L. Tinker Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer J Clin Oncol 27 2009 5577 (abstract)
63. C.M. Chresta, B.R. Davies, I. Hickson, T. Harding, S. Cosulich, and S.E. Critchlow AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Res 70 2010 288 298
64. C. Voliva, S. Pecchi, M. Burger, T. Nagel, C. Schnell, and C. Fritsch Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinositide 3-kinase in Phase I/II clinical trials AACR Annual Meeting 2010 4498 (poster)
65. G. Edelman, C. Bedell, G. Shapiro, S.S. Pandya, E.L. Kwak, and C. Scheffold A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies J Clin Oncol 28 2010 3004 (oral presentation)
66. N.T. Ihle, G. Paine-Murrieta, M.I. Berggren, A. Baker, W.R. Tate, and P. Wipf The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts Mol Cancer Ther 4 2005 1349 1357
67. D. Von Hoff, P. LoRusso, G. Demetri, G. Weiss, G. Shapiro, and R. Ramanathan A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors J Clin Oncol 29 2011 3052 (poster)
68. S.M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, and C. Fritsch Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol Cancer Ther 7 2008 1851 1863
69. P. Munster, R. van der Noll, E. Voest, E. Dees, A. Tan, and J. Specht Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826) J Clin Oncol 29 2011 3018 (poster)
70. I. Brana, P. LoRusso, J. Baselga, E.I. Heath, A. Patnaik, and S. Gendreau A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies J Clin Oncol 28 2010 3030 (poster)
71. A. Wagner, J. Bendell, S. Dolly, J. Morgan, J. Ware, and J. Fredrickson A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors J Clin Oncol 29 2011 3020 (poster)
72. T. Yap, L. Yan, A. Patnaik, D. Olmos, I. Fearen, and R. Baird Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers J Clin Oncol 29 2011 3001 (abstract)
73. J. Tabernero, C. Saura, D. Roda Perez, R. Dienstmann, S. Rosello, and L. Prudkin First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068 J Clin Oncol 29 2011 3022 (abstract)
74. H. Burris, L. Siu, J. Infante, J. Wheler, C. Kurkjian, and J. Opalinska Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study J Clin Oncol 29 2011 3003 (oral presentation)
75. U. Banerji, C. Aghajanian, E. Raymond, R. Kurzrock, M. Blanco-Codesido, and E. Oelmann First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor J Clin Oncol 29 2011 3096 (abstract)
76. D.S. Tan, H. Dumez, D. Olmos, S.K. Sandhu, A. Hoeben, and A.W. Stephens First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma J Clin Oncol 28 2010 3006 (abstract)
77. B. Graña, H.A. Burris III, J. Rodon, A. Razak, M.J. De Jonge, and F. Eskens Oral PI3 kinase inhibitor BKM120 monotherapy in patients with advanced solid tumors: an update on safety and efficacy J Clin Oncol 29 2011 3043 (abstract)
78. A. Jimeno, R.S. Herbst, G.S. Falchook, W.A. Messersmith, S. Hecker, and S. Peterson Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase J Clin Oncol 28 2010 3089 (abstract)
79. J. Peyton, H. Burris, J. Rodon, C. Britten, L.-C. Chen, and J. Tabernero A dose-escalation study of the oral dual PI3K-mTOR inhibitor BEZ235, using the novel special delivery system (SDS) sachet formulation, in patients with advanced solid tumors J Clin Oncol 29 2011 3066 (abstract)
80. D. Mahadevan, E. Chiorean, W. Harris, D. Von Hoff, A. Younger, and D. Rensvold Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies J Clin Oncol 29 2011 3015 (abstract)
81. N.T. Ihle, R. Lemos Jr. , P. Wipf, A. Yacoub, C. Mitchell, and D. Siwak Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance Cancer Res 69 2009 143 150
82. V. Serra, B. Markman, M. Scaltriti, P.J. Eichhorn, V. Valero, and M. Guzman NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 2008 8022 8030
83. L. Meyer, B. Slomovitz, B. Djordjevic, J. Galbincea, T. Johnston, and M. Munsell The search continues: looking for predictive biomarkers for response mTOR inhibition in endometrial cancer J Clin Oncol 29 2011 5016 (abstract)
84. S. Wee, Z. Jagani, K.X. Xiang, A. Loo, M. Dorsch, and Y.M. Yao PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res 69 2009 4286 4293
85. J.A. Engelman, L. Chen, X. Tan, K. Crosby, A.R. Guimaraes, and R. Upadhyay Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 2008 1351 1356
86. A.C. Faber, D. Li, Y. Song, M.C. Liang, B.Y. Yeap, and R.T. Bronson Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition Proc Natl Acad Sci U S A 106 2009 19503 19508
87. K.P. Hoeflich, C. O'Brien, Z. Boyd, G. Cavet, S. Guerrero, and K. Jung In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models Clin Cancer Res 15 2009 4649 4664
88. ClinicalTrials.gov [cited Jan 2011]. Available from: www.clinicaltrials. gov.
89. P. Chaudhry, and E. Asselin Resistance to chemotherapy and hormone therapy in endometrial cancer Endocr Relat Cancer 16 2009 363 380
90. C. Gu, Z. Zhang, Y. Yu, Y. Liu, F. Zhao, and L. Yin Inhibiting PI3K/Akt pathway reversed progestin resistance in endometrial cancer Cancer Sci 102 2011 557 564
91. X. Wan, J. Li, X. Xie, and W. Lu PTEN augments doxorubicin-induced apoptosis in PTEN-null Ishikawa cells Int J Gynecol Cancer 17 2007 808 812
92. T. Ohta, M. Ohmichi, T. Hayasaka, S. Mabuchi, M. Saitoh, and J. Kawagoe Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models Endocrinology 147 2006 1761 1769
93. S. Mabuchi, M. Ohmichi, A. Kimura, K. Hisamoto, J. Hayakawa, and Y. Nishio Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel J Biol Chem 277 2002 33490 33500
94. V.L. Bae-Jump, C. Zhou, J.F. Boggess, and P.A. Gehrig Synergistic effect of rapamycin and cisplatin in endometrial cancer cells Cancer 115 2009 3887 3896
95. A. Shafer, C. Zhou, P.A. Gehrig, J.F. Boggess, and V.L. Bae-Jump Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis Int J Cancer 126 2010 1144 1154
96. O. Treeck, B. Wackwitz, U. Haus, and O. Ortmann Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells Gynecol Oncol 102 2006 292 299
97. T. Eschenhagen, T. Force, M.S. Ewer, G.W. de Keulenaer, T.M. Suter, and S.D. Anker Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
98. S.S. Bandaru, K. Lin, S.L. Roming, R. Vellipuram, and J.P. Harney Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior Physiol Behav 100 2010 239 244
99. A. Polter, S. Yang, A.A. Zmijewska, T. van Groen, J.H. Paik, and R.A. Depinho Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation Biol Psychiatry 65 2009 150 159
100. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron Akt/GSK3 signaling in the action of psychotropic drugs Annu Rev Pharmacol Toxicol 49 2009 327 347
101. C. O'Brien, J.J. Wallin, D. Sampath, D. GuhaThakurta, H. Savage, and E.A. Punnoose Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models Clin Cancer Res 16 2010 3670 3683
102. G. Shapiro, P. LoRusso, E. Kwak, J. Cleary, L. Musib, and C. Jones Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a first-in-human phase IB study testing daily and intermittent dosing schedules in patients with advanced solid tumors J Clin Oncol 29 2011 3005 (abstract)
103. A.D. Tolcher, R.D. Baird, A. Patnaik, V. Moreno Garcia, K.P. Papadopoulos, and C.R. Garrett A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors J Clin Oncol 29 2011 3004 (abstract)